Elon Musk's Neuralink implants raise new concerns about brain surgery risks
- Neuralink has successfully implanted devices in three human patients with plans for more trials this year.
- The second patient has demonstrated the device's utility in playing video games and using design software.
- Neuralink's progress is part of a broader landscape of over 45 ongoing brain-computer interface trials in the U.S.
In the United States, Neuralink has made notable advancements in brain-computer interface technology, recently announcing that it has successfully implanted devices in three human patients, with plans to continue expanding its trials. The latest recipients include individuals with spinal cord injuries, who have reportedly shared positive experiences using the device. One patient expressed how it has facilitated playing video games and engaging with 3-D design software. These developments come after a significant update to the devices, enhancing their functionality with more electrodes, increased bandwidth, and longer battery life. While Neuralink garners public attention, it is essential to note that it is not the only entity working on similar brain-computer interface technology. Research around BCIs has been widespread, with numerous trials ongoing, over 45 identified through a database. Notably, research published in the New England Journal of Medicine last year highlighted how BCIs have improved communication among people with Amyotrophic Lateral Sclerosis (ALS). Additionally, experts have indicated that various companies and research labs are achieving significant milestones in this field, suggesting a competitive landscape. Rajesh Rao, a co-director at the University of Washington's Center for Neurotechnology, stated that Neuralink possesses some unique characteristics, particularly the use of robotic surgery to implant flexible electrode threads into the human brain. This method allows for the recording of neural activity and control of devices, potentially outperforming other conventional interfaces. However, Rao also cautioned that some competitors are already showing advanced methodologies that either employ less invasive techniques or combine neural recording with stimulation functionalities. Organizations like the Christopher & Dana Reeve Foundation express excitement regarding BCI technology's potential benefits for individuals with paralysis. Marco Baptista, the foundation's chief scientific officer, voiced support for high-risk, high-reward research but pointed out that they have not provided funding to Neuralink. He emphasized the need for careful evaluation regarding the safety and practicality of such technology before widespread adoption occurs. The journey of BCI devices involves rigorous testing and approval processes by the Food and Drug Administration (FDA) for high-risk medical devices to ensure they meet safety standards prior to market release.